GLP-1 Therapies Newsletter
Issue #53September 7, 20267 studies
Semaglutide slowed aging and extended lifespan in older female mice
GLP-1 drugs had a big week, and not just for waistlines.
From mouse longevity to cancer risk reduction to sleep apnea, the evidence keeps expanding—and so do the complications worth watching.
🐭 A Weight-Loss Drug Just Extended Mouse Lifespan
- Researchers treated 20-month-old female mice (roughly equivalent to late middle age) with semaglutide for 3 months. The drug improved physical function, dialed back biological markers of aging, and—when continued—extended lifespan.
- The effects closely mirrored calorie restriction, a well-studied longevity intervention. In direct comparison, semaglutide matched or outperformed calorie restriction on spatial memory, exploratory drive, and glucose control.
- This is mice, not humans, and only female mice at that. But the mechanistic overlap with calorie restriction gives researchers a framework for why GLP-1 drugs produce benefits that go well beyond appetite suppression.
Why it matters: It reframes semaglutide from a metabolic drug into something that may interact with core aging biology—a much bigger claim that now needs human investigation.
Key Findings
💊 Tirzepatide vs. Semaglutide: The Head-to-Head Numbers
- Across 10 studies and 41,381 participants, tirzepatide produced about 4.3 percentage points more weight loss than semaglutide, plus an extra 4.4 kg in absolute terms.
- The catch: serious adverse events were 83% more frequent with tirzepatide. Gastrointestinal side effects were similar between the two drugs.
💡 Tirzepatide wins on weight, but the safety gap deserves a closer look.
🔄 What Happens When You Stop
- A Bayesian meta-analysis reconstructed weight regain trajectories after stopping semaglutide or tirzepatide. The pattern is consistent: substantial weight returns after discontinuation, though the exact rate and ceiling remain uncertain.
- This reinforces that these drugs work while you take them—not as a one-time reset.
💡 Weight regain after stopping is real, measurable, and still not fully mapped.
🎗️ GLP-1 Drugs and Cancer Risk: A Large Signal
- A meta-analysis of 78 observational studies found GLP-1 receptor agonist use was associated with statistically significant reductions in 10 of 13 obesity-linked cancers, including colorectal, liver, and pancreatic cancers.
- Compared specifically to insulin, the risk reductions were striking—colorectal cancer risk was nearly halved. Thyroid cancer showed a slight uptick, but it didn't reach statistical significance.
💡 GLP-1 drugs may cut risk for multiple obesity-linked cancers—observational data, but hard to ignore.
😴 Sleep Apnea Gets a Drug—Now Who Benefits Most?
- Post-hoc analyses of the SURMOUNT-OSA trial examined which patients responded best to tirzepatide for obstructive sleep apnea. Tirzepatide reduced breathing disruptions and hypoxic burden across subgroups defined by age, sex, BMI, and neck circumference.
- Tirzepatide became the first FDA-approved drug for moderate-to-severe sleep apnea in people with obesity in December 2024.
💡 Tirzepatide works across sleep apnea subgroups—but who responds best is still being sorted.
🧠 Higher Semaglutide Dose, Fewer Neuropsychiatric Events
- In 63,215 patients with pre-existing neuropsychiatric conditions, higher attained semaglutide doses were associated with lower rates of mood disorders, substance-related disorders, anxiety, and several other neuropsychiatric diagnoses over two years.
- The effect appeared largely independent of weight loss—except for cognitive and speech symptoms, which tracked more closely with how much weight patients lost.
💡 Semaglutide's brain effects may go beyond weight loss—dose appears to matter independently.
👶 GLP-1 Prescriptions for Kids Ages 8–11 Are Rising
- A new study tracked GLP-1 receptor agonist prescriptions for children aged 8 to 11 from 2019 to 2026 and found a significant upward trend, particularly in children with more severe obesity and greater comorbidity burden.
- Clinical guidelines allow consideration of these drugs in this age group, but long-term safety data in young children remain limited.
💡 GLP-1 prescriptions in young children are climbing fast, ahead of long-term safety data.
Implications
GLP-1 drugs now touch oncology, neurology, aging biology, and pediatrics—all in a single week's literature. The central unresolved tension: nearly every new benefit signal comes from observational data or animal models, while the question of who should stop, switch, or never start these drugs remains genuinely open.
Studies in this issue
Primary sources used for this newsletter.
- Semaglutide treatment later in life slows aging and extends lifespan in female micemain storyNature2026-09-03PMID 42686906
- Tirzepatide’s links to changes in sleep apnea measures based on starting patient traitskey findingJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2026-08-31PMID 42675225
- Higher semaglutide doses linked to fewer mental health problems regardless of weight losskey findingnpj metabolic health and disease2026-09-02PMID 42680805
- Links Between Diabetes Drugs Called GLP-1 Receptor Agonists and Cancer Risk: A Review and Analysiskey findingCancer control : journal of the Moffitt Cancer Center2026-09-01PMID 42677883
- Changes in Prescriptions of GLP-1 Medicines for Children Ages 8 to 11 with Obesity from 2019 to 2026key findingPediatrics2026-09-03PMID 42692477
- Patterns of Weight Regain After Stopping Semaglutide or Tirzepatide Treatmentkey findingEndocrinology, diabetes & metabolism2026-08-31PMID 42673571
- Tirzepatide versus Semaglutide for Weight Loss in Adults with Overweight or Obesity: A Comparison Studykey findingClinical obesity2026-08-31PMID 42670242
Continue reading
All GLP-1 Therapies issuesGet the next GLP-1 Therapies issue
Seven papers, once a week. Free.